Surgical treatment of spontaneous cerebellar hemorrhage.
T N Lui, D J Fairholm, T F Shu...
https://pubmed.ncbi.nlm.nih.gov/3992454/Actively Recruiting
Led by Yanbing Yu · Updated on 2026-09-23
142
Participants Needed
15
Research Sites
26 weeks
Total Duration
Researchers are evaluating the use of robot-assisted stereotactic puncture surgery compared to conventional medical treatment for patients with brainstem hemorrhage. The study aims to create a multi-center clinical database, assess the effects of this minimally invasive surgery on survival and neurological outcomes, and improve the robotic surgical system with artificial intelligence for better planning and prediction. Participants are randomly assigned to either receive robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture or conventional conservative medical management. The surgical procedure uses AI-based robotic navigation to plan and perform precise puncture and aspiration of the hematoma, with individualized surgical approaches based on imaging. The control group receives standard medical care that includes oxygen therapy, blood pressure control, sedation, and other supportive treatments. During the study, participants will be monitored for survival at 60 days, neurological function and recovery using various scales at 60 days and 6 months, quality of life, cognitive function, and hospital and ICU stay lengths. Imaging will assess hematoma clearance in the first week after surgery, and complications such as pneumonia or seizures will be tracked within 14 days. The study will last until June 2028, with ongoing evaluations to understand safety and efficacy of the robotic surgery approach.
CONDITIONS
A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke
Y
Yanbing Yu, M.D.
Y
Yulian Zhang, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yanbing Yu
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 48 hours after onset for surgery; medical management duration varies
Participants receive either robot-assisted stereotactic minimally invasive surgery or standard medical management for brainstem hemorrhage.
Multiple visits during hospitalization and follow-up
Duration - 6 months
Participants are monitored for survival, neurological recovery, quality of life, cognitive function, hematoma clearance, and complications for up to 6 months after treatment.
Follow-up visits at 60 days and 6 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
T N Lui, D J Fairholm, T F Shu...
https://pubmed.ncbi.nlm.nih.gov/3992454/Yanbing Yu
Lead Sponsor